All Drug Development articles – Page 16
-
NewsDual-action therapy clears MDR bacteria in preclinical models
Centauri Therapeutics has published data showing that CTX-09’s ability effectively clears drug-resistant Gram-negative bacteria through a novel dual mechanism, marking a promising development for new infection therapies.
-
ArticleWhy playing it safe is slowing down drug discovery
President Trump’s proposed drug pricing reforms are putting pressure on early-stage discovery. To keep pace, teams must rethink how they manage risk, resources and collaboration.
-
NewsSB000: a safer path to anti-aging therapies
Shift Bioscience has announced new aging research, highlighting the discovery of SB000. This novel single-gene target reverses cellular aging without activating dangerous pluripotency pathways.
-
ArticleA global push for better animal welfare in research
What does ethical research look like in drug discovery today? In this interview, Charles River’s Executive Director of Global Animal Welfare shares how global standards, the 3Rs and her own path as a woman in STEM are shaping efforts to reduce animal use in science.
-
ArticleFrom siloed data to breakthroughs: multimodal AI in drug discovery
Drug development has long been hindered by fragmented data and complex processes, but a new wave of AI is reshaping the landscape. By integrating genomic, clinical and molecular data, multimodal models are revealing hidden patterns and accelerating more precise advancements in medicine.
-
NewsStatins repurposed for sepsis show life-saving potential
A new study suggests statins, cheap and widely used cholesterol drugs, could be repurposed to reduce the risk of death from sepsis. Researchers reported a 39 percent drop in 28-day mortality, highlighting their potential role in critical care.
-
ArticleShifting the ADC focus from antibody to payload
While ADCs continue to attract attention in oncology, many developers remain focused on antibodies – overlooking the critical role of payload design. At Sygnature Discovery, Dr Joshua Greally is leading a shift in perspective, advocating for a payload-first approach through the company’s new platform, NewPath ADC. In this interview, he ...
-
ArticleWhy radiopharmaceuticals are gaining ground in the fight against cancer
Radiopharmaceuticals represent a rapidly advancing field in oncology, using radioactive compounds to both detect and treat cancer at the molecular level. This article explores how targeted radiation is improving patient outcomes while reducing systemic toxicity.
-
ArticleAutomated red blood cell exchange: bridging treatment gaps in sickle cell disease care
Despite the promise of gene therapies, automated red blood cell exchange (aRBCX) remains an underutilised therapy in the management of sickle cell disease (SCD). In this article, Dr Aaron Haubner and Carly Newton of Terumo Blood and Cell Technologies, highlight the urgent need for partnerships and equitable access to this ...
-
NewsHerpes virus protein boosts T cell power against cancer
Researchers at the University of Michigan have engineered a herpes virus protein to enhance T cell survival and function, offering a new strategy to strengthen cancer immunotherapy.
-
NewsChemical hack turns platelets into drug couriers
Researchers at the University of Illinois have achieved the first successful metabolic labelling of platelets, a key step toward using them in targeted drug delivery. The technique could enable short-lived, precision therapies for cancer, immune conditions, and clotting disorders. ...
-
ArticleStrategic planning in ADC development: insights from Lonza
Preclinical and clinical development are critical to the success of ADCs, where early strategic decisions regarding manufacturability and scalability can make or break a project. Iwan Bertholjotti of Lonza emphasises the importance of proactive planning to avoid costly delays and ensure smooth progress towards clinical success.
-
NewsNew UCD centre targets the biggest bottleneck in rare research
The world’s first translational research center dedicated to urea cycle disorders (UCDs) has been launched in Zürich, marking a significant moment in rare disease innovation.
-
ArticleNew fixed-duration therapy could reshape CLL care
Advancements in chronic lymphocytic leukaemia (CLL) treatment, like the AMPLIFY Phase III trial combining acalabrutinib and venetoclax, offer less toxic and more effective options. Learn from AstraZeneca’s Benjamin Moutier about how this breakthrough highlights the potential of targeted therapies to improve outcomes and reduce treatment burden, marking a key moment ...
-
ArticleTransforming cancer care through clinical excellence
Melika Davis at BeOne reflects on the inspiration and drive that has helped her forge a successful career in clinical operations.
-
NewsNasal spray gene therapy shows potential to treat lung diseases
Researchers at Mass General Brigham have developed a new gene therapy delivery system, AAV.CPP.16, that targets the lungs via nasal spray, which could offer a potential breakthrough in respiratory gene therapy.
-
NewsNew investigational therapy shows promise for treating skeletal disorders
Tyra Biosciences has announced new data showing that its investigational therapy, TYRA-300, improves bone growth and corrects skeletal abnormalities in preclinical models of achondroplasia and hypochondroplasia.
-
NewsTargeting PLA2G15 to treat neurometabolic disorders
Scenic Biotech and Stanford University have published a study identifying PLA2G15 as a new drug target in neurodegenerative and metabolic diseases, potentially enabling future treatments for conditions like Niemann-Pick type C.
-
ArticleAI at the forefront of age-related disease treatment
The body undergoes changes with age that can lead to conditions like sarcopenia and osteoarthritis, burdening individuals and healthcare systems. Find out how Rejuvenate Biomed uses AI to decode ageing biology and develop combination therapies targeting the root causes of age-related diseases, offering hope for better treatments and quality of ...
-
NewsTargeting the clock: new drug disrupts glioblastoma stem cells
Scientists have developed a new drug, SHP1705, that targets hijacked circadian clock proteins used by glioblastoma stem cells to grow and resist treatment.